Clinical Trial Update: Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase I trial evaluating afatinib and dasatinib in non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• DASATINIB (Dasatinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Lung Cancer, Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Status: COMPLETED | Results posted: 2019-06-14